Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting

Clinical Diabetes and Endocrinology
Wayne WengTodd Hobbs

Abstract

This study evaluated the impact of atherosclerotic cardiovascular disease (ASCVD) on healthcare resource utilization and costs in patients with type 2 diabetes mellitus (T2DM). This study was a retrospective, cross-sectional study using US claims data. Adult patients with T2DM were stratified by presence or absence of ASCVD and compared regarding annual (2015) healthcare resource utilization and associated costs. Subgroup analyses were conducted for three age groups (18-44, 45-64, and ≥ 65 years). Among 1,202,596 eligible patients with T2DM, 45.2% had documented ASCVD. The proportions of patients with inpatient and ER-based resource utilization during 2015 were three-to-four times greater in the ASCVD cohort as compared to the non-ASCVD cohort for the categories of inpatient visits (15.6% vs 4.4% of patients), outpatient ER visits (18.4% vs 5.2% of patients), and inpatient ER visits (4.3% vs 0.9% of patients). Outpatient utilization also was higher among patients with ASCVD as compared to those without ASCVD (mean number of annual office visits per patient, 9.1 vs 5.6), and more than twice as many patients with ASCVD had ≥ 9 office visits (43.5% vs 19.8%). Average per-patient total healthcare cost was $22,977 for ASCVD vs $9735...Continue Reading

References

Mar 3, 2007·Journal of Diabetes and Its Complications·Reema ModyVivek Pawar
Jul 14, 2010·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·A A RivelleseO Vaccaro
Mar 8, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Mar 28, 2013·International Journal of Hypertension·Alessandra Saldanha de Mattos MatheusMarilia de Brito Gomes
Jul 21, 2015·Journal of Medical Economics·Stephen S JohnstonIftekhar Kalsekar
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Dec 17, 2016·Diabetes Care·UNKNOWN American Diabetes Association
Mar 3, 2018·Diabetes Research and Clinical Practice·N H ChoB Malanda
Jul 15, 2018·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Thomas R EinarsonUlrik H Panton

❮ Previous
Next ❯

Citations

Jun 14, 2020·Expert Review of Cardiovascular Therapy·Junyi Yang
May 30, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lars BernfortLars-Åke Levin

❮ Previous
Next ❯

Software Mentioned

SAS
MarketScan

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.